Dementia and Alzheimer Disease

Clive Ballard, MD, spoke on safety data presented at this year’s AAIC meeting, as well as the impact of symptoms associated with DRP, which can be distressing for individuals and their families.

The therapy, already FDA-approved for individuals with pulmonary artery disease, was significantly associated with reduced likelihood of Alzheimer disease in both the 65-74 year range and those older than 75 years.

Ballard, a professor of age related diseases at University of Exeter, discussed the results from a recent trial of pimavanserin in dementia-related psychosis, and data presented at this year’s AAIC meeting.

Findings presented at AAIC 2021 found that long-term, daily treatment with non-invasive stimulation was both safe and well-tolerated in patients with Alzheimer disease.

Pooled data from the phase 3 clinical development of aducanumab (Aduhelm; Biogen) suggest that ARIA remains a mostly asymptomatic problem, with MRI providing an effective way to monitor events.

The agent, which is FDA-approved for hyperlipidemia, showed significant improvements in plasma glucose, lipid levels, and trends in cardiovascular imaging biomarkers.

Many applicants referenced an early interest and exposure to neurology, often describing their first courses in neurology sparking their desire to learn more about how the brain works.

Here's what is coming soon to NeurologyLive.

The director of Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease, associate professor of neurology, Albert Einstein College of Medicine, discussed recent developments in Alzheimer disease research, including FDA approval of aducanumab, as well as the importance of engaging community-based organizations to improve patient care.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 23, 2021.

Alfred Sandrock, MD, PhD, head of research and development, Biogen, has published an open letter to the Alzheimer community in an attempt to clarify “misinformation and misunderstanding” that has moved “outside the boundaries of legitimate scientific deliberation.”

The director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease commented on social determinants of health in relation to telemedicine and community willingness to engage.

The Integrated Cognitive Assessment showed convergent validity with both MoCA and ACE and offers potential for remote measurement of cognitive performance in Alzheimer disease and mild cognitive impairment.

In Alzheimer disease and dementia, Jessica Zwerling, MD, MS, director, Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease, believes normalizing trial recruitment aids and telehealth to increase participation is another way to ease delivery of care.

The study data suggest that intervention strategies to improve antimicrobial and burdensome intervention for suspected LRIs and UTIs are ineffective.

Challenges surrounding the use of telehealth for patients with Alzheimer disease are affected by technological barriers, according to the associate director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease

The director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease discusses the use of telehealth for patients with Alzheimer disease during the COVID-19 pandemic, as well as her thoughts on why it is here to stay.

Here's what is coming soon to NeurologyLive.

Jessica Zwerling, MD, associate director, Center for the Aging Brain, Montefiore Medical Center, discussed the impact that telemedicine has had in Alzheimer and dementia care.

Neurology News Network for the week ending July 17, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 15, 2021.

Investigators found that certain underrepresented communities were less likely to be eligible for Alzheimer disease trials after the first screening visit.

The position statement considers the diagnosis of dementia, problems in decision making, symptoms and behavioral management, and the relationship between dementia care and society.

The observational study, initiated by Centogene in partnership with Alector, aims to identify and explore the frequency of genetic mutations in patients with frontotemporal dementia.

ATH-1017, an investigational agent designed to focus on network recovery and synaptic signal transition in the brain, will be evaluated in patients on cognition, global, and functional assessments.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 9, 2021.

Janet Woodcock, MD, acting commissioner of the FDA, called for an inquiry by the Office of the Inspector General into possible interactions between agency officials and Biogen that "may have occurred outside of the formal correspondence process."

Since 2016, there has been consistent growth in the number of Alzheimer disease trials sponsored both in part and fully by academic medical centers and/or the National Institutes of Health.

The newly updated label language emphasizes the Alzheimer disease stages in which aducanumab was studied, with no additional changes made to its approval pathway.